logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Dipeptidyl Peptidase 4 Inhibitor class drugs

    FiltersReset Filters
    10 results

    • glyxambi

      (empagliflozin and linagliptin)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: GLYXAMBI, a combination of empagliflozin and linagliptin, is indicated to improve glycemic control in adults with type 2 diabetes mellitus alongside diet and exercise. Empagliflozin also reduces cardiovascular death risk in patients with type 2 diabetes and existing cardiovascular disease. It is not suitable for type 1 diabetes or certain conditions.

    • janumet

      (SITAGLIPTIN and METFORMIN HYDROCHLORIDE)
      Merck Sharp & Dohme LLC
      Usage: JANUMET is indicated for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. It should not be used in type 1 diabetes and has not been studied in patients with a history of pancreatitis.

    • janumet

      (sitagliptin and metformin hydrochloride)
      Merck Sharp & Dohme LLC
      Usage: JANUMET XR is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It is not for use in patients with type 1 diabetes or those with a history of pancreatitis.

    • januvia

      (sitagliptin)
      Merck Sharp & Dohme LLC
      Usage: JANUVIA® is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It should not be used in type 1 diabetes and has not been studied in patients with a history of pancreatitis.

    • jentadueto

      (linagliptin and metformin hydrochloride)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: JENTADUETO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not recommended for patients with type 1 diabetes or a history of pancreatitis, as its effects in these populations are unclear.

    • steglujan

      (ertugliflozin and sitagliptin)
      Merck Sharp & Dohme LLC
      Usage: STEGLUJAN® is indicated to improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise. It is not recommended for type 1 diabetes or in patients with a history of pancreatitis due to unknown risks.

    • tradjenta

      (linagliptin)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: TRADJENTA is indicated for improving glycemic control in adults with type 2 diabetes mellitus, alongside diet and exercise. It is not recommended for type 1 diabetes patients and has not been studied in those with a history of pancreatitis.

    • trijardy xr

      (empagliflozin, linagliptin, metformin hydrochloride)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: TRIJARDY XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Additionally, empagliflozin, one of its components, helps reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

    • zituvimet xr

      (sitagliptin and metformin hydrochloride)
      Zydus Lifesciences Limited

    • zituvimet xr

      (sitagliptin and metformin hydrochloride)
      Zydus Pharmaceuticals USA Inc.
      Usage: ZITUVIMET XR is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus. It is not recommended for patients with type 1 diabetes or those with a history of pancreatitis, as its safety in such populations is not established.